Prana meeting with investors at world’s largest healthcare conference in San Francisco
Dr. David Stamler presenting at Biotech Showcase
Prana receives $3 million R&D Tax Incentive Refund
Prana has today announced that is has received a A$3.02 million cash refund under the Australian Government’s R&D Tax Incentive Scheme.
Annual General Meeting Presentation 2017
Prana AGM Investor Conference Call
Prana Biotechnology invites investors unable to attend the Annual General Meeting to participate via teleconference.
Annual Report Filed on Form 20-F with SEC
Prana has announced that it has filed its Annual Report on Form 20-F
Prana commences research collaboration with Takeda for the treatment of Parkinson’s disease gastrointestinal neuropathology
PBT434, Prana’s lead drug in preclinical development for movement disorders, to be profiled in collaborative venture
Prana’s PBT434 Lowers Alpha-Synuclein and Prevents Neurodegeneration
Scientific Journal Acta Neuropathologica publishes pre-clinical data
Prana Appoints David Stamler as Chief Medical Officer to Lead Clinical Development
David Stamler, M.D., has joined Prana Biotechnology (ASX PBT, NASDAQ PRAN) as Chief Medical Officer and Senior Vice President, Clinical Development, based in San Francisco.
Prana’s Anti-Parkinsonian compound PBT434 presented at 13th International Conference for Alzheimer’s & Parkinson’s Diseases
Prana today announced a scientific presentation demonstrating pre-clinical evidence for Prana’s PBT434 as a first-in-class disease modifying therapy for the treatment of Parkinsonian movement disorders that will be featured at the 13th International Conference for Alzheimer’s and Parkinson’s Diseases in Vienna from 29 March 2 April 2017.